FIELD: bioengineering.
SUBSTANCE: immune body is suggested that specifically links with human alpha-sinuclein containing mature variable regions of heavy and light chains with appropriate amino acid sequences. Pharmaceutical composition is disclosed for treatment or prevention of disease with Levy bodies, containing effective number of immune bodies.
EFFECT: invention ensures new immune body that specifically links with human alpha-sinuclein, and can be used for immunotherapy of the disease with Levy bodies.
5 cl, 6 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODIES THAT RECOGNIZE ALPHA-SYNUCLEINE | 2012 |
|
RU2743738C2 |
| HUMANIZED ANTIBODIES, WHICH RECOGNIZE ALPHA-SINUCLEIN | 2013 |
|
RU2642262C2 |
| HUMANISED ANTIBODIES TO LIV-1 AND USE THEREOF FOR TREATING CANCER | 2011 |
|
RU2608646C2 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2718990C1 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2697098C1 |
| UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
| MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
| AGENTS, APPLICATION WAYS AND METHODS FOR TREATING SYNUCLEOPATHY | 2016 |
|
RU2765303C2 |
| HUMANISED MONOCLONAL ANTIBODIES TO HEPATOCYTE GROWTH FACTOR | 2007 |
|
RU2461570C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
